Asked by amora
A brief description of the hemophilia disease
All Answers 1
Answered by
GPT-5 mini
AI
Hemophilia is an inherited bleeding disorder caused by a deficiency of specific blood-clotting proteins (clotting factors) that help stop bleeding. The two main types are hemophilia A (factor VIII deficiency) and hemophilia B (factor IX deficiency). Because the genes are on the X chromosome, hemophilia typically affects males while females are usually carriers.
Key points:
- Cause: genetic deficiency of clotting factor VIII (A) or IX (B).
- Inheritance: X-linked recessive (males symptomatic; females usually carriers).
- Main symptoms: prolonged bleeding after injuries or surgery, easy bruising, spontaneous bleeding into joints and muscles (leading to pain and joint damage).
- Diagnosis: prolonged activated partial thromboplastin time (aPTT) and specific factor assays to measure factor levels.
- Treatment: replacement therapy with clotting-factor concentrates (on-demand or regular prophylaxis), desmopressin (DDAVP) for some mild hemophilia A cases, antifibrinolytic medicines for mucosal bleeds, and emerging gene therapies; management also includes bleeding-avoidance measures and physiotherapy for joint health.
- Complications: joint destruction from repeated bleeds, development of inhibitors (antibodies) to replacement factors, and blood-borne infections from older blood products (much reduced with modern screening).
With appropriate treatment and preventive care, many people with hemophilia can lead active lives. For personal medical advice or testing, consult a hematologist.
Key points:
- Cause: genetic deficiency of clotting factor VIII (A) or IX (B).
- Inheritance: X-linked recessive (males symptomatic; females usually carriers).
- Main symptoms: prolonged bleeding after injuries or surgery, easy bruising, spontaneous bleeding into joints and muscles (leading to pain and joint damage).
- Diagnosis: prolonged activated partial thromboplastin time (aPTT) and specific factor assays to measure factor levels.
- Treatment: replacement therapy with clotting-factor concentrates (on-demand or regular prophylaxis), desmopressin (DDAVP) for some mild hemophilia A cases, antifibrinolytic medicines for mucosal bleeds, and emerging gene therapies; management also includes bleeding-avoidance measures and physiotherapy for joint health.
- Complications: joint destruction from repeated bleeds, development of inhibitors (antibodies) to replacement factors, and blood-borne infections from older blood products (much reduced with modern screening).
With appropriate treatment and preventive care, many people with hemophilia can lead active lives. For personal medical advice or testing, consult a hematologist.
Submit Your Answer
We prioritize human answers over AI answers.
If you are human, and you can answer this question, please submit your answer.